Video Link: https://www.youtube.com/watch?v=9R1nc9tIN7w

Cancer drug reduces MS relapses
From Cambridge - A drug used to treat cancer has shown great success in reducing multiple sclerosis disease activity, according to two trials published in the Lancet. In the first trial, over 500 MS patients who had yet to undergo any treatment for their disease, were randomized to receive the cancer drug alemtuzumab or interferon beta 1a, the most common treatment for MS. After two years follow-up, results showed that those only 22% of patients on the cancer drug relapsed, while 40% of those on interferon beta 1a relapsed. In the second study, nearly 900 patients who had already been treated with initial therapy and suffered a relapse were randomized to either alemtuzumab or interferon beta 1a or glatiramer, another common MS drug. As in the first trial, patients taking alemtuzumab were significantly less likely to relapse than those taking interferon beta 1a or glatiramer. In addition, alemtuzumab was associated with a reduction in disease-related disabilityFrom:insidermedicineViews:4 0ratingsTime:00:57More inScience Technology

See the original post:
Cancer drug reduces MS relapses - Video